<DOC>
	<DOC>NCT02501200</DOC>
	<brief_summary>A randomized, open-label, 2-way crossover study to compare the pharmacokinetics and safety CKD-391 to coadministration Atorvastatin and Ezetimibe in health volunteers.</brief_summary>
	<brief_title>CKD-391 Pharmacokinetic Study Phase I</brief_title>
	<detailed_description>To compare the CKD-391 (Experimental product) to the dose Atorvastatin calcium and Ezetimibe combination in health male subjects is the purpose of this trial. Following are evaluated in this trial; Characteristics and safety/Tolerability Of CKD-391.</detailed_description>
	<mesh_term>Ezetimibe</mesh_term>
	<criteria>Bwt &gt;=50kg, BMI 18.5~25 signed the informed consent form prior to the study participation Clinically significant disease Subject has signs of symptoms of acute disease within 28 days of starting administration of investigational drug Clinically significant allergic disease Impossible to taking the institutional standard meal Previously donate whole blood within 60 days or component blood within 20 days Previously participated in other trial within 90 days Continued to be taking caffeine (caffeine &gt; 5 cup/day), drinking(alcohol &gt; 30 g/day) or cannot stop drinking or severe heavy smoker(cigarette &gt; 10 cigarettes per day)during clinical trials An impossible one who participates in clinical trial by investigator's decision including laboratory test result</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Dyslipidemia</keyword>
	<keyword>CKD-391</keyword>
	<keyword>Atorvastatin</keyword>
	<keyword>Ezetimibe</keyword>
</DOC>